Actively Recruiting

Age: 18Years +
All Genders
NCT06926179

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Led by Peking University Cancer Hospital & Institute · Updated on 2025-04-16

500

Participants Needed

4

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.

CONDITIONS

Official Title

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed non-small cell lung cancer (NSCLC), regardless of EGFR or ALK mutations
  • Clinical stage IA to IIIC according to AJCC 8th Edition before neoadjuvant treatment
  • Received at least one cycle of neoadjuvant immunotherapy with or without chemotherapy
  • Assessed as resectable or potentially resectable by surgical experts before treatment
Not Eligible

You will not qualify if you...

  • Confirmed M1 disease (distant metastasis)
  • History of previous lung malignancy or other metastatic malignant tumors
  • Participation in other randomized controlled trials involving neoadjuvant treatment
  • Significant missing clinical data

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Peking University Cancer Hospital & Institute

Beijing, Beijing Municipality, China, 100142

Actively Recruiting

2

Peking University Third Hospital

Beijing, Beijing Municipality, China

Actively Recruiting

3

Inner Mongolia Hospital of Peking University Cancer Hospital

Hohhot, Inner Mongolia, China

Actively Recruiting

4

The Third Affliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Actively Recruiting

Loading map...

Research Team

N

Nan Wu, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer | DecenTrialz